<DOC>
	<DOCNO>NCT02784496</DOCNO>
	<brief_summary>The goal clinical research study collect data long term safety tolerability ruxolitinib give patient MF .</brief_summary>
	<brief_title>Study Ruxolitinib Patients With Myelofibrosis ( MF )</brief_title>
	<detailed_description>If participant agrees take part study , continue receive ruxolitinib prescribe Study 2007-0169 . In addition , participant study visit ( describe ) help researcher collect data side effect may effect , , ruxolitinib and/or disease . Study Drug Administration : Each study cycle 28 day . Participant take ruxolitinib tablet mouth cup water ( 8 ounce ) either 1 2 time day . Participant continue receive ruxolitinib dose schedule assign Study 2007-0169 . The study staff remind participant schedule assign . Participant also give study drug diary write take dose ruxolitinib miss vomit dos . Participant bring diary clinic visit MD Anderson . Study Visits : At every visit , participant ask side effect may new drug ( over-the-counter drug , prescription drug , and/or herbal/dietary supplement ) take plan take . Every 6 cycle ( ± 30 day ) : - Participant physical exam . - Blood ( 2-3 tablespoon ) draw routine test . - Participant complete 2 questionnaire quality life . They take 10 minute complete . Every 3 cycle , participant call study doctor member study staff ask side effect may answer question might study . This call last 10 minute . On Day 1 Cycle 3 every 3 cycle ( Cycles 6 , 9 , 12 , ) ( +/- 14 day ) , blood ( 2-3 tablespoon ) draw routine test . Participant may choose blood draw perform local lab clinic closer home . The result test send study doctor MD Anderson . The study doctor discus option participant . Length Study : Participant may continue take ruxolitinib long doctor think best interest . Participant longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Patient 's participation study follow-up . End-of-Study Visit : As soon possible participant 's last dose study drug , doctor think need : - Blood ( 2-3 tablespoon ) draw routine test . - Participant complete physical exam . - Participant complete 2 questionnaire quality life . This investigational study . Ruxolitinib FDA approve commercially available treat MF . It consider investigational collect data long-term effect ruxolitinib . The study doctor explain study drug design work . Up 14 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<criteria>1 . Currently enrol study 20070169 benefiting therapy determine treat physician , 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 enrollment study 3 . Ability agreement attend protocolspecified visit study site 4 . Able comprehend willing sign inform consent form 5 . Negative pregnancy test female childbearing potential . Male patient female partner childbearing potential female patient childbearing potential require use two form acceptable contraception , include one barrier method , participation study 30 day follow last dose . Acceptable form contraception include 1 highly effective method intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation , partner 's vasectomy least 1 additional approve barrier method latex condom , diaphragm , cervical cap . Female patient childbearing potential must breastfeed plan breast feed must negative pregnancy test ≤7 day first study treatment . 1 ) None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Primary Myelofibrosis</keyword>
	<keyword>PMF</keyword>
	<keyword>Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis</keyword>
	<keyword>Post-PV/ET MF</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>Jakafi</keyword>
	<keyword>INCB018424</keyword>
	<keyword>INC424</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
</DOC>